Boulder, Colorado-based Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is discovering solutions for cystic fibrosis. The company is developing a class of disease-modifying therapies designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell-signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease causing mutation in CF. For more information, visit the company’s website atwww.nivalis.com.